Exelixis
EXEL
#2109
Rank
$7.53 B
Marketcap
$26.42
Share price
-1.53%
Change (1 day)
22.83%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : $0.65 B

According to Exelixis's latest financial reports the company's total liabilities are $0.65 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31$0.67 B16.36%
2022-12-31$0.58 B43.74%
2021-12-31$0.40 B57.08%
2020-12-31$0.25 B29.3%
2019-12-31$0.19 B48.11%
2018-12-31$0.13 B-63.59%
2017-12-31$0.37 B-26.87%
2016-12-31$0.50 B7.03%
2015-12-31$0.47 B8%
2014-12-31$0.43 B0.24%
2013-12-31$0.43 B2.92%
2012-12-31$0.42 B40.32%
2011-12-31$0.30 B-48.63%
2010-12-31$0.58 B16.17%
2009-12-31$0.50 B10.76%
2008-12-31$0.45 B40.19%
2007-12-31$0.32 B7.15%
2006-12-31$0.30 B10.67%
2005-12-31$0.27 B14.44%
2004-12-31$0.24 B22.6%
2003-12-31$0.19 B20.29%
2002-12-31$0.16 B49.18%
2001-12-31$0.10 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
$56.04 B 8,477.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$60.84 B 9,212.05%๐Ÿ‡ซ๐Ÿ‡ท France
$68.98 B 10,457.60%๐Ÿ‡บ๐Ÿ‡ธ USA
$77.57 B 11,773.06%๐Ÿ‡บ๐Ÿ‡ธ USA
$84.98 B 12,906.38%๐Ÿ‡บ๐Ÿ‡ธ USA
$109.55 B 16,666.48%๐Ÿ‡บ๐Ÿ‡ธ USA
$128.21 B 19,523.59%๐Ÿ‡บ๐Ÿ‡ธ USA
$51.1 M-92.18%๐Ÿ‡บ๐Ÿ‡ธ USA
$72.38 M-88.92%๐Ÿ‡บ๐Ÿ‡ธ USA